months before 85%. and after implant. + brachy implant. Zelefsky N/A - Size of Not all 1997 7.5mg prostatic patients (n=214) monthly tumours in were from 3 relation to months before RT cancer structures. until last In the 45 day of RT patients treatment prospectively + evaluated, the median reduction after daily administration from of NHT was 68 3/12 mL, prior to representing a last day 27 % + reduction in the size of the 3D target volume. RT The 3 Year actuarial survival and disease-free survival rates were 93 %, and 83%, respectively. Fransson Substudy - Assessed Locally Moderate to QoL type 2009 of 3/12 for 1 severe urinary endpoints Widmark year, then 64 were ‘bother’ 2009 6/12, then (18%) on focussed at 1, 2, cancer ADT+RT vs 39 upon in 4, 8 and 10. (12%) on ADT this (p=0.005) substudy. Generally, QoL at 4 years there were similar apart more from problems decreased in those social function receiving in those RT. receiving RT+ADT Lund Substudy - 5 Locally Genrally Nil 2013 of higher symptom
months before and after implant. + brachy implant. 85%. Zelefsky 1997 (n=214) 7.5mg monthly from 3 months before RT until last day of RT treatment + daily from 3/12 prior to last day + 3D RT N/A - cancer Size of prostatic tumours in relation to structures. In the 45 patients prospectively evaluated, the median reduction after administration of NHT was 68 mL, representing a 27 % reduction in the size of the target volume. The 3 Year actuarial survival and disease-free survival rates were 93 %, and 83%, respectively. Not all patients were Fransson 2009 Substudy of Widmark 2009 - Assessed 3/12 for 1 year, then 6/12, then at 1, 2, 4, 8 and 10. Locally cancer Moderate to severe urinary ‘bother’ 64 (18%) on ADT+RT vs 39 (12%) on ADT (p=0.005) QoL at 4 years similar apart from decreased social function in those receiving RT+ADT QoL type endpoints were focussed upon in this substudy. Generally, there were more problems in those receiving RT. Lund 2013 Substudy of - 5 Locally Genrally higher symptom Nil